Osborne Clarke advises LEO PHARMA

Published on 5th April 2024

Default News Article Image

Osborne Clarke has advised LEO PHARMA, a world leader in pharmaceutical products for dermatology and thrombosis, on the negotiation of the commercial lease for its new head office in the Ampere E+ building in La Défense, Europe's leading business district.

LEO PHARMA has been advised by Osborne Clarke's Real Estate team: 

Share
Media comment

Our legal experts are available to provide comment or background on international legal issues for your publication.

Contact our press team
Related articles
Osborne Clarke advises parking technology company Unity5 on acquisition of Chipside including its product MiPermit
28/03/2025 • 1 mins
Osborne Clarke advises Public First on sale to Stonehaven Group
27/03/2025 • 1 mins
Osborne Clarke advises Virgin Money on £30m revolving credit facility for Gresham House forestry fund
27/03/2025 • 2 mins
Osborne Clarke advises firstminute capital in connection with EUR 55 million Series B funding round of software company n8n GmbH
27/03/2025 • 1 mins

Connect with one of our experts